
ENTX
Healthcare · Biotechnology · $541.6M market cap
$3.11-0.11 (-3.4%)Nov 13, 4:26 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -38.9% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2026 | After the close | -0.07 | -0.11 | -57.1% |
| Aug 7, 2026 | Time not confirmed | -0.08 | -0.14 | -75.0% |
| May 8, 2026 | After the close | -0.08 | -0.07 | +12.5% |
| Mar 27, 2026 | Time not confirmed | -0.11 | -0.06 | +45.5% |
| Nov 14, 2025 | After the close | -0.09 | -0.07 | +22.2% |
| Aug 8, 2025 | After the close | -0.11 | -0.06 | +45.5% |
| May 9, 2025 | After the close | -0.07 | -0.06 | +14.3% |
| Mar 6, 2025 | Before the open | -0.08 | -0.06 | +25.0% |
| Nov 8, 2024 | After the close | -0.05 | -0.08 | -60.0% |
| Aug 9, 2024 | After the close | -0.06 | -0.06 | 0.0% |
| May 10, 2024 | After the close | -0.06 | -0.05 | +16.7% |
| Mar 8, 2024 | After the close | -0.08 | -0.07 | +12.5% |
| Nov 14, 2023 | Before the open | -0.09 | -0.08 |
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide…
| +11.1% |
| Aug 11, 2023 | After the close | -0.07 | -0.08 | -14.3% |
| May 5, 2023 | After the close | -0.12 | -0.08 | +33.3% |
| Mar 31, 2023 | After the close | -0.11 | -0.10 | +9.1% |
| Nov 10, 2022 | After the close | -0.13 | -0.11 | +15.4% |
| Aug 11, 2022 | Before the open | -0.16 | -0.11 | +31.3% |
| May 12, 2022 | Before the open | -0.18 | -0.13 | +27.8% |
| Mar 8, 2022 | Before the open | -0.23 | -0.21 | +8.7% |
| Nov 10, 2021 | Before the open | -0.11 | -0.05 | +54.5% |
| Aug 16, 2021 | Before the open | -0.12 | -0.21 | -75.0% |
| May 20, 2021 | Before the open | -0.12 | -0.43 | -258.3% |
| Mar 18, 2021 | Before the open | -0.14 | -0.13 | +7.1% |
| Nov 19, 2020 | Before the open | -0.20 | -0.09 | +55.0% |
| Aug 20, 2020 | Before the open | -0.12 | -0.17 | -41.7% |
| May 21, 2020 | Before the open | — | 0.16 | — |
| Mar 26, 2020 | Before the open | -0.19 | -0.26 | -36.8% |
| Nov 21, 2019 | Before the open | -0.15 | -0.25 | -66.7% |
| Aug 20, 2019 | Before the open | -0.28 | -0.12 | +57.1% |
| Jun 27, 2019 | Before the open | — | -0.26 | — |
| Mar 28, 2019 | Before the open | -0.35 | -0.17 | +51.4% |
| Sep 30, 2018 | Time not confirmed | -0.28 | -0.45 | -60.7% |
| Aug 20, 2018 | After the close | -0.09 | -0.16 | -77.8% |
| Jun 29, 2018 | After the close | -0.08 | -0.08 | 0.0% |
| Jan 5, 2018 | Time not confirmed | — | -0.31 | — |